Results 211 to 220 of about 12,500,740 (339)

Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK, EGFR, and KRAS genetic alterations

open access: yesMolecular Oncology, EarlyView.
Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi   +12 more
wiley   +1 more source

Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma. [PDF]

open access: yesHemasphere
Garces JJ   +28 more
europepmc   +1 more source

Complex Numbers and Physical Reality

open access: green, 2001
V.V. Lyahov, V.M. Nechshadim
openalex   +2 more sources

Introducing Complex Numbers into Basic Growth Functions (6) : Hypothetic Breakdown of '1' into Complex Numbers and Application to Definite Integral of exp(t) Expanded into Infinite Series [PDF]

open access: bronze, 2005
Masataka Shimojo   +9 more
openalex   +1 more source

Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs

open access: yesMolecular Oncology, EarlyView.
In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza   +3 more
wiley   +1 more source

Centromere protection requires strict mitotic inactivation of the Bloom syndrome helicase complex. [PDF]

open access: yesNat Commun
Fernández-Casañas M   +8 more
europepmc   +1 more source

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

open access: yesMolecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy